(Trospium chloride + xanomeline) is under clinical development by Karuna Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Trospium chloride + xanomeline)’s likelihood of approval (LoA) and phase transition for Psychosis took place on 09 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Trospium chloride + xanomeline) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Trospium chloride + xanomeline) overview

Xanomeline in combination with trospium chloride is under development for the treatment of psychosis, negative and cognitive symptoms associated with dementia, dementia-related psychosis, schizophrenia as an adjunctive treatment for psychosis associated with Alzheimer’s disease. It is administered orally. The drug candidate act by targeting muscarinic acetyl choline receptors. It was also under development for the treatment of bipolar disorder and pain.

Karuna Therapeutics overview

Karuna Therapeutics, formerly Karuna Pharmaceuticals, is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. It is investigating its lead product candidate KarXT, an oral modulator of muscarinic receptors for the treatment of schizophrenia, negative and cognitive symptoms of schizophrenia, and Alzheimer’s disease. The company is also evaluating muscarinic-targeted and target-agnostic drug candidates for various indications. Its lead product candidate combines xanomeline, a novel muscarinic agonist that stimulates muscarinic receptors in the central nervous system. Karuna Therapeutics is headquartered in Boston, Massachusetts, the US.

Quick View (Trospium chloride + xanomeline) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Trospium chloride + xanomeline)
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.